The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Can GKT137831 - a NOX Inhibitor - Stop Liver Fibrosis?

Back to News Homepage

Next

Hep C Trial with Sovaprevir Has 85% Success Rate

Heart Problem Pauses Hepatitis C Drug Study

August 8, 2012

Print this page

Trials on one of Bristol-Myers’ potential Hepatitis C drugs, BMS-986094, have been halted to investigate a possible case of related heart failure.

Bristol-Myers suspends hepatitis C treatment study, cites possible cardiac concern

Article by: TOM MURPHY , Associated Press

Updated: August 2, 2012 – 11:34 AM

Drugmaker Bristol-Myers Squibb Co. is suspending a midstage study of a potential hepatitis C treatment after at least one patient suffered heart failure.

The New York company hasn’t determined the cause or whether it is tied to the potential treatment, so it is examining all patients who took the drug.

Continue reading this entire article:
http://www.startribune.com/lifestyle/health/164724656.html?refer=y%22,,0,0,,,,

2 Comments
Share
Share

Previous

Can GKT137831 - a NOX Inhibitor - Stop Liver Fibrosis?

Back to News Homepage

Next

Hep C Trial with Sovaprevir Has 85% Success Rate

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.